G-CSF Administered in Time-sequenced Setting During Remission Induction and Consolidation Therapy of Adult Acute Lymphoblastic Leukemia has Beneficial Influence on Early Recovery and Possibly Improves Long-term Outcome: A Randomized Multicenter Study
Autor: | Sławomira Krzemień, Wojciech Baran, Maria Cioch, Aleksander B. Skotnicki, Stanisław Maj, Beata Hołowiecka, Sebastian Giebel, Jerzy Wojnar, Lech Konopka, Małgorzata Kopera, Tadeusz Robak, Małgorzata Krawczyk-Kuliś, Jerzy Holowiecki, Sebastian Grosicki, Anna Dmoszynska, Monika Paluszewska, Krystyna Jagoda, Andrzej Hellmann, Wojciechowska M |
---|---|
Rok vydání: | 2002 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment acute lymphoblastic leukemia G-CSF Infections Granulopoiesis Gastroenterology Drug Administration Schedule Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor cytokine medicine Humans induction Survival rate Chemotherapy business.industry Remission Induction Hematology Length of Stay Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma Granulocyte colony-stimulating factor Surgery Survival Rate Haematopoiesis Treatment Outcome Oncology Adult Acute Lymphoblastic Leukemia Female Untreated Adult Acute Lymphoblastic Leukemia business Agranulocytosis Epirubicin medicine.drug |
Zdroj: | Leukemia & Lymphoma. 43:315-325 |
ISSN: | 1029-2403 1042-8194 |
Popis: | Sixty-four untreated adult acute lymphoblastic leukemia (ALL) patients were randomized to receive chemotherapy alone, n = 31 or chemotherapy and granulocyte colony stimulating factor (G-CSF), n = 33. During induction patients received G-CSF for 5 days between four weekly Epirubicin+Vcr administrations, starting 36 h after each application and finishing 48 h before the next one with the intention to possibly generate a cell cycle dependent protection of normal hematopoietic progenitors and to stimulate granulopoiesis. The complete remission (CR) rate equaled 94% in the G-CSF group and 87% in controls. Patients who received G-CSF, if compared to the controls, had shorter granulocytopenia during induction and consolidation, displayed a lower infection rate, completed the induction-consolidation quicker and stayed shorter in hospital during induction, p < 0.001-0.04. Follow-up at 2 years revealed a rather higher probability of survival (59 vs. 27%, p = 0.04) and a lower relapse rate (32 vs. 60%) in G-CSF arm than in controls. The beneficial influence of G-CSF administered in time-sequenced fashion on survival needs further confirmation. |
Databáze: | OpenAIRE |
Externí odkaz: |